Cypress Bioscience, Inc. to Present at Oppenheimer 21st Annual Healthcare Conference
03 Novembre 2010 - 11:30AM
Marketwired
Cypress Bioscience, Inc. (NASDAQ: CYPB) today
announced that Sabrina Martucci Johnson, its Chief Operating
Officer and Chief Financial Officer, will present at Oppenheimer's
21st Annual Healthcare Conference today, November 3, 2010.
The Oppenheimer conference is being held at the Waldorf=Astoria
Hotel in New York, NY. Ms. Johnson is scheduled to present on
Wednesday, November 3rd at 10:15 am Eastern Time. The audio
broadcast of this presentation can be accessed at
http://www.veracast.com/webcasts/opco/healthcare2010/44204459.cfm.
A replay of the presentation will be available at the same web
address as well as on Cypress' website,
http://www.cypressbio.com/events.php.
About Cypress Bioscience Cypress
Bioscience is a pharmaceutical company dedicated to the development
of innovative drugs targeting large unmet medical needs for
patients suffering from a variety of disorders of the central
nervous system. Since 1999, Cypress has received FDA approvals for
both of the products it brought to the FDA during that period,
including for Prosorba™, a medical device for rheumatoid arthritis,
and Savella® (milnacipran HCl), for fibromyalgia. The Company
focuses on generating stockholder value by reaching clinical
development milestones as quickly and efficiently as possible.
Cypress' development-stage assets include CYP-1020 for cognitive
impairment in schizophrenia, Staccato® nicotine for smoking
cessation and intranasal carbetocin for autism. More information on
Cypress and its products and development assets is available at
http://www.cypressbio.com/.
For more information about Cypress, please visit the Company's
website at www.cypressbio.com.
For additional information please contact Mary Gieson
Investor Relations Manager (858) 452-2323 Email Contact
Cypress Bioscience (NASDAQ:CYPB)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Cypress Bioscience (NASDAQ:CYPB)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Cypress Bioscience, Inc. (MM) (NASDAQ): 0 recent articles
Plus d'articles sur Cypress Bioscience, Inc.